胃癌离体组织三维培养模型在免疫细胞抗肿瘤能力研究中的应用进展<sup>*</sup>

doi:10.3969/j.issn.1671-7171.2025.10.001

Abstract
Figure/Table
References (0)
Related Citation (15)

[1] ALZEEB G, METGES J P, CORCOS L, et al. Three-dimensional culture systems in gastric cancer research[J].Cancers (Basel),2020,12(10):2800.
[2] OBREQUE J, VERGARA-GÓMEZ L, VENEGAS N, et al. Advances towards the use of gastrointestinal tumor patient-derived organoids as a therapeutic decision-making tool[J].Biol Res,2023,56(1):63.
[3] SUN P M, XU Y X, DU X H, et al. An engineered three-dimensional gastric tumor culture model for evaluating the antitumor activity of immune cells in vitro[J].Oncol Lett,2013,5(2):489-494.
[4] FONTANA F, MARZAGALLI M, SOMMARIVA M, et al. In vitro 3D cultures to model the tumor microenvironment[J].Cancers (Basel),2021,13(12):2970.
[5] ABUWATFA W H, PITT W G, HUSSEINI G A. Scaffold-based 3D cell culture models in cancer research[J].J Biomed Sci,2024,31(1):7.
[6] COLOMBANI T, ROGERS Z J, BHATT K, et al. Hypoxia-inducing cryogels uncover key cancer-immune cell interactions in an oxygen-deficient tumor microenvironment[J].Bioact Mater,2023:279-295.
[7] BHATTACHARYA S, CALAR K, DE LA PUENTE P. Mimicking tumor hypoxia and tumor-immune interactions employing three-dimensional in vitro models[J].J Exp Clin Cancer Res,2020,39(1):75.
[8] XU X, FARACH-CARSON M C, JIA X Q. Three-dimensional in vitro tumor models for cancer research and drug evaluation[J].Biotechnol Adv,2014,32(7):1256-1268.
[9] JUBELIN C, MUÑOZ-GARCIA J, GRISCOM L, et al. Three-dimensional in vitro culture models in oncology research[J].Cell Biosci,2022,12(1):155.
[10] MARQUES J R O F, GONZÁLEZ-ALVA P, LIN R Y T, et al. Advances in tissue engineering of cancer microenvironment-from three-dimensional culture to three-dimensional printing[J].SLAS Technol,2023,28(3):152-164.
[11] BREGENZER M E, HORST E N, MEHTA P, et al. Integrated cancer tissue engineering models for precision medicine[J].PLoS One,2019,14(5):e0216564.
[12] LI M Y, JIANG P, WEI S H, et al. The role of macrophages-mediated communications among cell compositions of tumor microenvironment in cancer progression[J].Front Immunol,2023,14:1113312.
[13] GHEBREMEDHIN A, ATHAVALE D, ZHANG Y, et al. Tumor-associated macrophages as major immunosuppressive cells in the tumor microenvironment[J].Cancers (Basel),2024,16(19):3410.
[14] LIU D, JENKINS R W, SULLIVAN R J. Mechanisms of resistance to immune checkpoint blockade[J].Am J Clin Dermatol,2019,20(1):41-54.
[15] ZHANG H, LIU L, LIU J B, et al. Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers[J].Mol Cancer,2023, 22(1): 58.
[16] XIE Y F, XIE F, ZHANG L, et al. Targeted anti-tumor immunotherapy using tumor infiltrating cells[J].Adv Sci (Weinh),2021,8(22):e2101672.
[17] JIANG J T, WU C P, LU B F. Cytokine-induced killer cells promote antitumor immunity[J].J Transl Med,2013,11:83.
[18] SHI L R, ZHOU Q, WU J, et al. Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer[J].Cancer Immunol Immunother,2012, 61(12): 2251-2259.
[19] DAI C Q, LIN F J, GENG R X, et al. Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer[J].Oncotarget,2016,7(9):10332-10344.
[20] ZHANG H, LIU L, LIU J B, et al. Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers[J].Mol Cancer,2023,22(1):58.
[21] VRÁNA D, MATZENAUER M, NEORAL Č, et al. From tumor immunology to immunotherapy in gastric and esophageal cancer[J].Int J Mol Sci,2018,20(1):13.
[22] LI J, CHEN L J, XIONG Y Q, et al. Knockdown of PD-L1 in human gastric cancer cells inhibits tumor progression and improves the cytotoxic sensitivity to CIK therapy[J].Cell Physiol Biochem,2017, 41(3): 907-920.
[23] NAKAYAMA Y, MIMURA K, KUA L F, et al. Immune suppression caused by PD-L2 expression on tumor cells in gastric cancer[J]. Gastric Cancer,2020,23(6):961-973.
[24] LIU J W, LI H, SUN L P, et al. Profiles of PD-1, PD-L1, PD-L2 in gastric cancer and their relation with mutation, immune infiltration, and survival[J].Biomed Res Int,2020, 2020: 2496582.
[25] MATSUNAGA T, SAITO H, IKEGUCHI M. Increased B7-H1 and B7-H4 expressions on circulating monocytes and tumor-associated macrophages are involved in immune evasion in patients with gastric cancer[J].Yonago Acta Med,2011,54(1):1-10.
[26] FOULON A, THERET P, RODAT-DESPOIX L, et al. Beyond chemotherapies: recent strategies in breast cancer treatment[J].Cancers (Basel),2020,12(9):2634.
[27] HOU A H, HOU K Y, HUANG Q B, et al. Targeting myeloid-derived suppressor cell, a promising strategy to overcome resistance to immune checkpoint inhibitors[J].Front Immunol,2020, 11: 783.
[28] GOLUBOVSKAYA V. Editorial on special issue "immunotherapy, tumor microenvironment and survival signaling"[J].Cancers,2021, 14(1): 91.
[29] ZHAO Y, BAI Y S, SHEN M L, et al. Therapeutic strategies for gastric cancer targeting immune cells: future directions[J].Front Immunol,2022,13:992762.
[30] YE Y Q, YANG W Y, RUAN X J, et al. Metabolism-associated molecular classification of gastric adenocarcinoma[J].Front Oncol,2022,12:1024985.
[31] MASHUKOV A, SHAPOCHKA D, SELEZNOV O, et al. Histological differentiation impacts the tumor immune microenvironment in gastric carcinoma: Relation to the immune cycle[J].World J Gastroenterol,2021,27(31):5259-5271.
[32] BINTINTAN V, BURZ C, PINTEA I, et al. Predictive factors of immunotherapy in gastric cancer: a 2024 update[J].Diagnostics (Basel),2024,14(12):1247.
[33] PANG M J, BURCLAFF J R, JIN R, et al. Gastric organoids: progress and remaining challenges[J].Cell Mol Gastroenterol Hepatol,2022,13(1):19-33.
[34] JIANG C Y, ZHANG J J, WANG W T, et al. Extracellular vesicles in gastric cancer: role of exosomal lncRNA and microRNA as diagnostic and therapeutic targets[J].Front Physiol,2023,14:1158839.

[1]	. [J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(8): 1297-1300.